Clinical Trial Search

Primary: Objective Response at 48 to 72 Hours (FDA Primary Endpoint) — 259; 266; 72; 63 Participants

Primary: Kaplan-Meier Estimates for Time to Meaningful Pain Relief — 42.917; NA minutes

Primary: Change From Baseline to Day 84 (Week 12) in Numeric Pain Rating Scale Score — -1.6; -1.6 units on a scale — p=0.4503

Primary: Subjective Improvement - Day 3 (Rating of "a Lot Better" or "no Symptoms") — 33; 31; 22; 33 Participants

Primary: Total Sensory Neuropathy as Measured by the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life [QLQ] - Chemo-induced Peripheral…

Primary: Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change — 0.07; 0.07 units on a scale

Primary: Change From Baseline in Mean Menstrual Cramping Pain Score Through Cycle 2 — -1.7; -1.7; -1.9; -1.7 Units on a scale — p=< 0.001

Primary: Number of Participants With Objective Response Rate (ORR), of GSK1363089, Per- Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0 — 0; 0…

Primary: Physical Activity — 576.9; 572.4; 555.7 counts/minute of physical activity

Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 3; 4; 7; 0 Participants

Primary: Safety Lab Evaluations — -4.0; 0.1; 0.2; 1.1 percentage change from baseline

Primary: Change in Weight — 1.0; -5.3; -2.3; -4.3 pounds

Primary: Percent of Participants With Final Clinical Cure — 78.6; 77.8 percent of participants

Primary: The Percent Reduction in Post Void Dribbling Episodes (Events) — 59.8; 42.1 percent reduction — p=.1135

Primary: The Primary Safety Endpoint Will be the Combined Rate of Major Complications With in 30 +/- 7 Days Following the Percutaneous Coronary Intervention (PCI) Procedure. — 1…